Treatment exposure and response
| . | VDCR n = 48 . | VDR n = 42 . | VDC n = 33 . | VDC-mod n = 17 . |
|---|---|---|---|---|
| Patient experience on study | ||||
| Median follow-up, mo | 20 | 20 | 22 | 15 |
| Median cycles, n (range) | 5 (1-12) | 6 (1-12) | 6 (3-12) | 6 (3-12) |
| Completed induction, n (%) | 16 (33) | 17 (40) | 15 (45) | 7 (41) |
| Completed maintenance, n (%) | 12 (25) | 8 (19) | 10 (30) | 5 (29) |
| Confirmed response at cycle 4* | n = 40 | n = 41 | n = 32 | n = 17 |
| Complete response | 2 (5) | 3 (7) | 1 (3) | 2 (12) |
| sCR | 1 (3) | 1 (2) | 0 | 2 (12) |
| VGPR or better | 13 (33) | 13 (32) | 4 (13) | 7 (41) |
| ORR (PR or better) | 32 (80) | 30 (73) | 20 (63) | 14 (82) |
| Progression | 0 | 0 | 0 | 0 |
| Best response across all cycles | ||||
| Complete response | 10 (25) | 10 (24) | 7 (22) | 8 (47) |
| sCR | 6 (15) | 7 (17) | 3 (9) | 5 (29) |
| VGPR or better | 23 (58) | 21 (51) | 13 (41) | 9 (53) |
| ORR (PR or better) | 35 (88) | 35 (85) | 24 (75) | 17 (100) |
| Progression | 1 (3) | 1 (2) | 1 (3) | 0 |
| Best response across all cycles among patients ≤ 65 y | n = 28 | n = 28 | n = 21 | n = 12 |
| Complete response | 6 (21) | 6 (21) | 2 (10) | 7 (58) |
| VGPR or better | 15 (54) | 17 (61) | 5 (24) | 8 (67) |
| ORR (PR or better) | 24 (86) | 26 (93) | 14 (67) | 12 (100) |
| . | VDCR n = 48 . | VDR n = 42 . | VDC n = 33 . | VDC-mod n = 17 . |
|---|---|---|---|---|
| Patient experience on study | ||||
| Median follow-up, mo | 20 | 20 | 22 | 15 |
| Median cycles, n (range) | 5 (1-12) | 6 (1-12) | 6 (3-12) | 6 (3-12) |
| Completed induction, n (%) | 16 (33) | 17 (40) | 15 (45) | 7 (41) |
| Completed maintenance, n (%) | 12 (25) | 8 (19) | 10 (30) | 5 (29) |
| Confirmed response at cycle 4* | n = 40 | n = 41 | n = 32 | n = 17 |
| Complete response | 2 (5) | 3 (7) | 1 (3) | 2 (12) |
| sCR | 1 (3) | 1 (2) | 0 | 2 (12) |
| VGPR or better | 13 (33) | 13 (32) | 4 (13) | 7 (41) |
| ORR (PR or better) | 32 (80) | 30 (73) | 20 (63) | 14 (82) |
| Progression | 0 | 0 | 0 | 0 |
| Best response across all cycles | ||||
| Complete response | 10 (25) | 10 (24) | 7 (22) | 8 (47) |
| sCR | 6 (15) | 7 (17) | 3 (9) | 5 (29) |
| VGPR or better | 23 (58) | 21 (51) | 13 (41) | 9 (53) |
| ORR (PR or better) | 35 (88) | 35 (85) | 24 (75) | 17 (100) |
| Progression | 1 (3) | 1 (2) | 1 (3) | 0 |
| Best response across all cycles among patients ≤ 65 y | n = 28 | n = 28 | n = 21 | n = 12 |
| Complete response | 6 (21) | 6 (21) | 2 (10) | 7 (58) |
| VGPR or better | 15 (54) | 17 (61) | 5 (24) | 8 (67) |
| ORR (PR or better) | 24 (86) | 26 (93) | 14 (67) | 12 (100) |
V indicates bortezomib; D, dexamethasone; R, lenalidomide; C, cyclophosphamide; and VDC-mod, VDC plus a day 15 dose of C; CR, complete response; SCT, stem cell transplantation; sCR, stringent complete response; VGPR, very good partial response; PR, partial response; and ORR, objective response rate.
Ten patients were not evaluable for response.